Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: Two-year outcomes

Peter A. Campochiaro, Gulnar Hafiz, Roomasa Channa, Syed M. Shah, Quan Dong Nguyen, Howard Ying, Diana V. Do, Ingrid Zimmer-Galler, Sharon D. Solomon, Jennifer U. Sung, Beena Syed

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Purpose: To determine the long-term effects of intraocular antagonism of vascular endothelial growth factor (VEGF) in patients with macular edema caused by retinal vein occlusions (RVOs). Design: Prospective randomized trial. Participants: Twenty patients with macular edema caused by branch RVOs (BRVOs) and 20 patients with central RVOs (CRVOs). Methods: After the month 3 primary end point, patients were seen every 2 months and received injections of an anti-VEGF agent as needed for recurrent edema. Main Outcome Measures: Mean change from baseline best-corrected visual acuity (BCVA) at month 24 with assessment of other parameters of visual function and center subfield thickness (foveal thickness [FTH]). Results: For 17 patients with BRVO who completed 2 years of follow-up, the mean improvement from baseline in BCVA at month 24 was 17.8 letters compared with 15.6 letters at month 3. Improvement by at least 6, 3, or 2 lines occurred in 18%, 59%, and 76% of patients, respectively. The Snellen equivalent BCVA at month 24 was 20/40 or better in 10 patients. With an average of 2 injections of ranibizumab during year 2, the mean FTH at month 24 was 245.8 μm compared with 217.1 μm at month 3 and 481.5 μm at baseline. For 14 patients with CRVO who completed 2 years of follow-up, the mean improvement in BCVA at month 24 was 8.5 letters compared with 12.0 letters at month 3. Improvement by at least 6, 3, or 2 lines occurred in 14%, 21%, and 43% of patients, respectively. The Snellen equivalent BCVA at month 24 was 20/40 or better in 4 patients. With an average of 3.5 injections of ranibizumab in year 2, mean FTH at month 24 was 338 μm compared with 278 μm at month 3 and 533 μm at baseline. Duration of RVO >1 year at study entry and nonperfusion of perifoveal capillaries for 360 degrees correlated with reduced visual outcomes. Conclusions: Antagonism of VEGF provides substantial long-term benefit to patients with macular edema caused by RVO, but frequent injections are required in some patients with BRVO and most patients with CRVO. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.

Original languageEnglish (US)
Pages (from-to)2387-2394.e5
JournalOphthalmology
Volume117
Issue number12
DOIs
StatePublished - Dec 2010

Fingerprint

Retinal Vein Occlusion
Macular Edema
Vascular Endothelial Growth Factor A
Visual Acuity
Injections
Disclosure
Retinal Vein
Edema

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Campochiaro, P. A., Hafiz, G., Channa, R., Shah, S. M., Nguyen, Q. D., Ying, H., ... Syed, B. (2010). Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: Two-year outcomes. Ophthalmology, 117(12), 2387-2394.e5. https://doi.org/10.1016/j.ophtha.2010.03.060

Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions : Two-year outcomes. / Campochiaro, Peter A.; Hafiz, Gulnar; Channa, Roomasa; Shah, Syed M.; Nguyen, Quan Dong; Ying, Howard; Do, Diana V.; Zimmer-Galler, Ingrid; Solomon, Sharon D.; Sung, Jennifer U.; Syed, Beena.

In: Ophthalmology, Vol. 117, No. 12, 12.2010, p. 2387-2394.e5.

Research output: Contribution to journalArticle

Campochiaro, PA, Hafiz, G, Channa, R, Shah, SM, Nguyen, QD, Ying, H, Do, DV, Zimmer-Galler, I, Solomon, SD, Sung, JU & Syed, B 2010, 'Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: Two-year outcomes', Ophthalmology, vol. 117, no. 12, pp. 2387-2394.e5. https://doi.org/10.1016/j.ophtha.2010.03.060
Campochiaro, Peter A. ; Hafiz, Gulnar ; Channa, Roomasa ; Shah, Syed M. ; Nguyen, Quan Dong ; Ying, Howard ; Do, Diana V. ; Zimmer-Galler, Ingrid ; Solomon, Sharon D. ; Sung, Jennifer U. ; Syed, Beena. / Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions : Two-year outcomes. In: Ophthalmology. 2010 ; Vol. 117, No. 12. pp. 2387-2394.e5.
@article{614c9280334b4e06b73f085125a65706,
title = "Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: Two-year outcomes",
abstract = "Purpose: To determine the long-term effects of intraocular antagonism of vascular endothelial growth factor (VEGF) in patients with macular edema caused by retinal vein occlusions (RVOs). Design: Prospective randomized trial. Participants: Twenty patients with macular edema caused by branch RVOs (BRVOs) and 20 patients with central RVOs (CRVOs). Methods: After the month 3 primary end point, patients were seen every 2 months and received injections of an anti-VEGF agent as needed for recurrent edema. Main Outcome Measures: Mean change from baseline best-corrected visual acuity (BCVA) at month 24 with assessment of other parameters of visual function and center subfield thickness (foveal thickness [FTH]). Results: For 17 patients with BRVO who completed 2 years of follow-up, the mean improvement from baseline in BCVA at month 24 was 17.8 letters compared with 15.6 letters at month 3. Improvement by at least 6, 3, or 2 lines occurred in 18{\%}, 59{\%}, and 76{\%} of patients, respectively. The Snellen equivalent BCVA at month 24 was 20/40 or better in 10 patients. With an average of 2 injections of ranibizumab during year 2, the mean FTH at month 24 was 245.8 μm compared with 217.1 μm at month 3 and 481.5 μm at baseline. For 14 patients with CRVO who completed 2 years of follow-up, the mean improvement in BCVA at month 24 was 8.5 letters compared with 12.0 letters at month 3. Improvement by at least 6, 3, or 2 lines occurred in 14{\%}, 21{\%}, and 43{\%} of patients, respectively. The Snellen equivalent BCVA at month 24 was 20/40 or better in 4 patients. With an average of 3.5 injections of ranibizumab in year 2, mean FTH at month 24 was 338 μm compared with 278 μm at month 3 and 533 μm at baseline. Duration of RVO >1 year at study entry and nonperfusion of perifoveal capillaries for 360 degrees correlated with reduced visual outcomes. Conclusions: Antagonism of VEGF provides substantial long-term benefit to patients with macular edema caused by RVO, but frequent injections are required in some patients with BRVO and most patients with CRVO. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.",
author = "Campochiaro, {Peter A.} and Gulnar Hafiz and Roomasa Channa and Shah, {Syed M.} and Nguyen, {Quan Dong} and Howard Ying and Do, {Diana V.} and Ingrid Zimmer-Galler and Solomon, {Sharon D.} and Sung, {Jennifer U.} and Beena Syed",
year = "2010",
month = "12",
doi = "10.1016/j.ophtha.2010.03.060",
language = "English (US)",
volume = "117",
pages = "2387--2394.e5",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions

T2 - Two-year outcomes

AU - Campochiaro, Peter A.

AU - Hafiz, Gulnar

AU - Channa, Roomasa

AU - Shah, Syed M.

AU - Nguyen, Quan Dong

AU - Ying, Howard

AU - Do, Diana V.

AU - Zimmer-Galler, Ingrid

AU - Solomon, Sharon D.

AU - Sung, Jennifer U.

AU - Syed, Beena

PY - 2010/12

Y1 - 2010/12

N2 - Purpose: To determine the long-term effects of intraocular antagonism of vascular endothelial growth factor (VEGF) in patients with macular edema caused by retinal vein occlusions (RVOs). Design: Prospective randomized trial. Participants: Twenty patients with macular edema caused by branch RVOs (BRVOs) and 20 patients with central RVOs (CRVOs). Methods: After the month 3 primary end point, patients were seen every 2 months and received injections of an anti-VEGF agent as needed for recurrent edema. Main Outcome Measures: Mean change from baseline best-corrected visual acuity (BCVA) at month 24 with assessment of other parameters of visual function and center subfield thickness (foveal thickness [FTH]). Results: For 17 patients with BRVO who completed 2 years of follow-up, the mean improvement from baseline in BCVA at month 24 was 17.8 letters compared with 15.6 letters at month 3. Improvement by at least 6, 3, or 2 lines occurred in 18%, 59%, and 76% of patients, respectively. The Snellen equivalent BCVA at month 24 was 20/40 or better in 10 patients. With an average of 2 injections of ranibizumab during year 2, the mean FTH at month 24 was 245.8 μm compared with 217.1 μm at month 3 and 481.5 μm at baseline. For 14 patients with CRVO who completed 2 years of follow-up, the mean improvement in BCVA at month 24 was 8.5 letters compared with 12.0 letters at month 3. Improvement by at least 6, 3, or 2 lines occurred in 14%, 21%, and 43% of patients, respectively. The Snellen equivalent BCVA at month 24 was 20/40 or better in 4 patients. With an average of 3.5 injections of ranibizumab in year 2, mean FTH at month 24 was 338 μm compared with 278 μm at month 3 and 533 μm at baseline. Duration of RVO >1 year at study entry and nonperfusion of perifoveal capillaries for 360 degrees correlated with reduced visual outcomes. Conclusions: Antagonism of VEGF provides substantial long-term benefit to patients with macular edema caused by RVO, but frequent injections are required in some patients with BRVO and most patients with CRVO. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.

AB - Purpose: To determine the long-term effects of intraocular antagonism of vascular endothelial growth factor (VEGF) in patients with macular edema caused by retinal vein occlusions (RVOs). Design: Prospective randomized trial. Participants: Twenty patients with macular edema caused by branch RVOs (BRVOs) and 20 patients with central RVOs (CRVOs). Methods: After the month 3 primary end point, patients were seen every 2 months and received injections of an anti-VEGF agent as needed for recurrent edema. Main Outcome Measures: Mean change from baseline best-corrected visual acuity (BCVA) at month 24 with assessment of other parameters of visual function and center subfield thickness (foveal thickness [FTH]). Results: For 17 patients with BRVO who completed 2 years of follow-up, the mean improvement from baseline in BCVA at month 24 was 17.8 letters compared with 15.6 letters at month 3. Improvement by at least 6, 3, or 2 lines occurred in 18%, 59%, and 76% of patients, respectively. The Snellen equivalent BCVA at month 24 was 20/40 or better in 10 patients. With an average of 2 injections of ranibizumab during year 2, the mean FTH at month 24 was 245.8 μm compared with 217.1 μm at month 3 and 481.5 μm at baseline. For 14 patients with CRVO who completed 2 years of follow-up, the mean improvement in BCVA at month 24 was 8.5 letters compared with 12.0 letters at month 3. Improvement by at least 6, 3, or 2 lines occurred in 14%, 21%, and 43% of patients, respectively. The Snellen equivalent BCVA at month 24 was 20/40 or better in 4 patients. With an average of 3.5 injections of ranibizumab in year 2, mean FTH at month 24 was 338 μm compared with 278 μm at month 3 and 533 μm at baseline. Duration of RVO >1 year at study entry and nonperfusion of perifoveal capillaries for 360 degrees correlated with reduced visual outcomes. Conclusions: Antagonism of VEGF provides substantial long-term benefit to patients with macular edema caused by RVO, but frequent injections are required in some patients with BRVO and most patients with CRVO. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.

UR - http://www.scopus.com/inward/record.url?scp=78649880482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649880482&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2010.03.060

DO - 10.1016/j.ophtha.2010.03.060

M3 - Article

C2 - 20630595

AN - SCOPUS:78649880482

VL - 117

SP - 2387-2394.e5

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 12

ER -